US FDA approves Roivant-Priovant's skin and muscle disease drug

The US FDA has approved Lisraya, a drug by Roivant-Priovant, for the treatment of dermatomyositis, a rare skin and muscle disease.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 28 Aug 2026 and 31 Aug 2026.